Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States.

Kunimoto D, Ohji M, Maturi RK, Sekiryu T, Wang Y, Pan G, Li XY, Schneider S; BAMBOO and CYPRESS Study Groups.

Ophthalmic Surg Lasers Imaging Retina. 2019 Feb 1;50(2):e10-e22. doi: 10.3928/23258160-20190129-13.

PMID:
30768224
2.

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.

Callanan D, Kunimoto D, Maturi RK, Patel SS, Staurenghi G, Wolf S, Cheetham JK, Hohman TC, Kim K, López FJ, Schneider S.

J Ocul Pharmacol Ther. 2018 Nov 9. doi: 10.1089/jop.2018.0062. [Epub ahead of print]

3.

Effects of Shambhavi Mahamudra Kriya, a Multicomponent Breath-Based Yogic Practice ( Pranayama), on Perceived Stress and General Well-Being.

Peterson CT, Bauer SM, Chopra D, Mills PJ, Maturi RK.

J Evid Based Complementary Altern Med. 2017 Oct;22(4):788-797. doi: 10.1177/2156587217730934. Epub 2017 Sep 22.

4.

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.

Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK; Diabetic Retinopathy Clinical Research Network.

JAMA Ophthalmol. 2018 Jan 1;136(1):29-38. doi: 10.1001/jamaophthalmol.2017.4914.

5.

Yoga, Meditation and Mind-Body Health: Increased BDNF, Cortisol Awakening Response, and Altered Inflammatory Marker Expression after a 3-Month Yoga and Meditation Retreat.

Cahn BR, Goodman MS, Peterson CT, Maturi R, Mills PJ.

Front Hum Neurosci. 2017 Jun 26;11:315. doi: 10.3389/fnhum.2017.00315. eCollection 2017.

6.

Reply.

Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM.

Retina. 2017 Mar;37(3):e37-e40. doi: 10.1097/IAE.0000000000001548. No abstract available.

PMID:
28225729
7.

Therapeutic Options in Refractory Diabetic Macular Oedema.

Shah SU, Maturi RK.

Drugs. 2017 Apr;77(5):481-492. doi: 10.1007/s40265-017-0704-6. Review.

PMID:
28197794
8.
9.

INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.

Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group.

Retina. 2016 Jun;36(6):1143-52. doi: 10.1097/IAE.0000000000001004.

PMID:
26871523
10.

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial.

Kuppermann BD, Goldstein M, Maturi RK, Pollack A, Singer M, Tufail A, Weinberger D, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex® ERIE Study Group.

Ophthalmologica. 2015;234(1):40-54. doi: 10.1159/000381865. Epub 2015 Jun 18.

12.

Reply: To PMID 24531021.

Chang W, Garg SJ, Hsu J, Sivalingam A, Gupta SA, Regillo CD, Ho AC, Maturi R.

Am J Ophthalmol. 2015 Feb;159(2):404-5. doi: 10.1016/j.ajo.2014.10.022. No abstract available.

PMID:
25542554
14.

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group.

Ophthalmology. 2014 Oct;121(10):1904-14. doi: 10.1016/j.ophtha.2014.04.024. Epub 2014 Jun 4.

15.

Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.

Chang W, Garg SJ, Maturi R, Hsu J, Sivalingam A, Gupta SA, Regillo CD, Ho AC.

Am J Ophthalmol. 2014 Jun;157(6):1250-7. doi: 10.1016/j.ajo.2014.02.007. Epub 2014 Feb 13.

PMID:
24531021
16.

Regenerative therapeutic potential of adipose stromal cells in early stage diabetic retinopathy.

Rajashekhar G, Ramadan A, Abburi C, Callaghan B, Traktuev DO, Evans-Molina C, Maturi R, Harris A, Kern TS, March KL.

PLoS One. 2014 Jan 9;9(1):e84671. doi: 10.1371/journal.pone.0084671. eCollection 2014.

17.

Plasticity of visual attention in Isha yoga meditation practitioners before and after a 3-month retreat.

Braboszcz C, Cahn BR, Balakrishnan B, Maturi RK, Grandchamp R, Delorme A.

Front Psychol. 2013 Dec 12;4:914. doi: 10.3389/fpsyg.2013.00914. eCollection 2013.

18.

Screening, prevention, and ambitious management of diabetic macular edema in patients with type 1 diabetes.

Tarantola RM, Maturi RK, Kushal S, Gupta S.

Curr Diab Rep. 2013 Oct;13(5):679-86. doi: 10.1007/s11892-013-0410-z. Review.

PMID:
23959793
19.

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M.

Ophthalmology. 2012 Nov;119(11):2312-8. doi: 10.1016/j.ophtha.2012.08.022. Epub 2012 Sep 19. Erratum in: Ophthalmology. 2014 Mar;121(3):805.

20.

Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.

Diabetic Retinopathy Clinical Research Network; Writing Committee, Aiello LP, Beck RW, Bressler NM, Browning DJ, Chalam KV, Davis M, Ferris FL 3rd, Glassman AR, Maturi RK, Stockdale CR, Topping TM.

Ophthalmology. 2011 Dec;118(12):e5-14. doi: 10.1016/j.ophtha.2011.09.058.

Supplemental Content

Loading ...
Support Center